Shanghai RAAS Blood Products Co., Ltd.: Business Overview, Financials & Competitive Analysis
Shanghai RAAS Blood Products Co., Ltd. scores 7/10 on the AskCyborg Cyborg Score (Solid). Established plasma-derived therapeutics leader in China with strong domestic market position, but facing undisclosed operational concerns warranting investor caution. RAAS holds a market cap of approximately $6.4B with trailing 12-month revenue of $1.09B as of mid-2025, demonstrating solid scale and profitability in the niche plasma-derived therapeutics.
What is Shanghai RAAS Blood Products Co., Ltd.'s industry? Shanghai RAAS Blood Products Co., Ltd. operates in Pharmaceuticals - Plasma-Derived Therapeutics & Blood Products. AskCyborg classifies Shanghai RAAS Blood Products Co., Ltd. under Pharmaceuticals - Plasma-Derived Therapeutics & Blood Products in its company registry.
Shanghai RAAS Blood Products engages in the manufacture and sale of blood products in China. The company offers human serum albumin, human intravenous immunoglobulin, human coagulation factor VIII, human prothrombin c...
Cyborg Score thesis
Established plasma-derived therapeutics leader in China with strong domestic market position, but facing undisclosed operational...
Read the full analyst-debate transcript →Get the Latest Shanghai RAAS Blood Products Co., Ltd. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeShanghai RAAS Blood Products Co., Ltd. Overview
Pro stress-test →Shanghai RAAS Blood Products engages in the manufacture and sale of blood products in China. The company offers human serum albumin, human intravenous immunoglobulin, human coagulation factor VIII, human prothrombin complex, human fibrinogen, human thrombin and human fibrin adhesive, human immunoglobulin, hepatitis B immunoglobulin, tetanus immunoglobulin, and rabies immunoglobulin products. Founded in October 1988 as the first large sino-foreign joint venture in production of blood products.
Strategic Profile
Pro stress-test →RAAS is a blood products manufacturer in China with high comprehensive utilization of plasma raw materials and is engaged in the research, development, and manufacture of blood products and plasma-derived medical products. China accounts for 96.6% of net sales, providing strong domestic market penetration. The company made a merger/acquisition deal with Nanyue Biopharming on March 26, 2025, signaling growth through consolidation.
Competitive Landscape
Pro stress-test →Shanghai RAAS operates in the plasma-derived therapeutics segment dominated by global players like Grifols, CSL Limited, and domestic Chinese competitors. The company maintains a strong domestic competitive advantage through established supply chains and regulatory relationships, but faces increasing competition from both international firms and emerging local manufacturers in the Chinese blood products market.
Industry Context
Shanghai RAAS Blood Products Co., Ltd. operates in Pharmaceuticals - Plasma-Derived Therapeutics & Blood Products.
Key facts
Founded: 1988 · Headquarters: Shanghai, China · Employees: 3350 · Revenue: $1.09B · Market cap: $6.36B